Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
UNSPSC Code:
12352204
NACRES:
NA.21
Specific activity:
≥30 units/mg protein
Recombinant:
expressed in E. coli
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Enhanced Microbial Transglutaminase, Glycosylation tolerant, for site-specific antibody bioconjugation
recombinant
expressed in E. coli
Quality Segment
specific activity
≥30 units/mg protein
technique(s)
protein mass spectrometry: suitable
shipped in
dry ice
storage temp.
-10 to -25°C
General description
eMTG (Enhanced Microbial Transglutaminase) is an enzyme that catalyzes the formation of new isopeptide bonds between the primary amine of a drug linker and glutamine residues at position Q295 of IgG-type antibodies to produce site-specifically conjugated antibody-drug conjugates (ADCs).
Application
Site-specific conjugation is increasingly used in drug research, development, and manufacturing to produce ADCs and bioconjugates with defined drug-to-antibody ratios (DAR) since the resulting homogeneity improves safety and efficacy. Transglutaminase (TG)-mediated bioconjugation is a promising means of conjugating drug linkers specifically to the Q295 position of antibodies. However, its use traditionally requires antibody or glycan engineering since the adjacent glycosylation at N297 interferes with the TG reaction. If you are interested in trying eMTG to make therapeutic ADCs but do not currently have the conjugation setup/expertise, please consider ADC Express ™Service for pre-clinical lead candidate selection.
Features and Benefits
• Increased efficiency - with one-step bioconjugation for ADCs
• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product
• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates
• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.
• Glycosylation-tolerant - no need to remove glycosylation allowing for a preserved glycan on the antibody conjugate product
• Built for purpose - eMTG has been designed for producing ADCs and bioconjugates
• For higher-grade quality suitable for cGMP manufacturing of ADCs, please reach out using this form https://www.sigmaaldrich.com/US/en/services/contract-manufacturing/adc-bioconjugation/adc-bioconjugation-request-information with eMTG selected.
Other Notes
One unit will catalyze the formation of 1.0 micromole of hydroxamate per minute from N Z GLN-GLY and hydroxylamine at pH 6.0 at 37°C.
Legal Information
ADC EXPRESS is a trademark of Merck KGaA, Darmstadt, Germany
Palabra de advertencia
Danger
Códigos de peligro
Indicaciones de precaución
Hazard Classifications
Resp. Sens. 1
Clase de almacenamiento
11 - Combustible Solids
¿Qué está pasando?
WGK 1
Elija entre una de las versiones más recientes:
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
